中药联合或不联合常规西药治疗COVID-19的临床研究证据综述
本证据综述纳入58项临床研究,评估中药联合或不联合常规西药治疗COVID-19的疗效与安全性。汇总分析显示,中药联合常规西药在降低加重率方面优于单用常规西药,且未增加不良事件风险,但现有证据确定性低。
要点
- 中药联合常规西药可能降低COVID-19加重率,且不增加不良事件风险。
- 最常研究的中药包括连花清瘟颗粒/胶囊、血必净注射液和麻杏石甘汤。
- 现有证据确定性低,无高质量随机对照试验。
核心结论
- 当前低确定性证据提示,中药联合常规西药治疗COVID-19可能优于单用常规西药,且不增加不良事件风险。
研究设计与样本
- 纳入58项临床研究,包括10项随机对照试验、1项非随机对照试验、11项有对照组的回顾性研究、12项病例系列和24项病例报告。
主要发现
- 在加重率方面,干预组与对照组存在统计学差异(RR 0.42,95% CI 0.21至0.82,六项随机对照试验;RR 0.38,95% CI 0.23至0.64,五项有对照组的回顾性研究)。
- 与单用常规西药相比,中药联合常规西药在提高恢复率、缩短发热咳嗽乏力持续时间、提高核酸检测转阴率、提高胸部CT表现改善率及缩短胸部CT表现改善时间方面具有潜在优势。
- 不良事件方面,汇总数据显示中药组与对照组之间无统计学差异。
关键数值与推荐
- 最常测试的口服中成药、中药注射剂或中药汤剂为连花清瘟颗粒/胶囊、血必净注射液和麻杏石甘汤。
临床怎么用
- 在常规西药治疗基础上,可考虑联合使用中药(如连花清瘟、血必净或麻杏石甘汤)以可能降低加重率并改善症状,但需知晓证据确定性低。
局限性
- 未发现高质量随机对照试验,现有证据确定性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To present the evidence of the therapeutic effects and safety of Chinese herbal medicine (CHM) used with or without conventional western therapy for COVID-19. Methods: Clinical studies on the therapeutic effects and safety of CHM for COVID-19 were included. We summarized the general characteristics of included studies, evaluated methodological quality of randomized controlled trials (RCTs) using the Cochrane risk of bias tool, analyzed the use of CHM, used Revman 5.4 software to present the risk ratio (RR) or mean difference (MD) and their 95% confidence interval (CI) to estimate the therapeutic effects and safety of CHM. Results: A total of 58 clinical studies were identified including RCTs (17.24%, 10), non-randomized controlled trials (1.72%, 1), retrospective studies with a control group (18.97%, 11), case-series (20.69%, 12) and case-reports (41.38%, 24). No RCTs of high methodological quality were identified. The most frequently tested oral Chinese patent medicine, Chinese herbal medicine injection or prescribed herbal decoction were: Lianhua Qingwen granule/capsule, Xuebijing injection and Maxing Shigan Tang. In terms of aggravation rate, pooled analyses showed that there were statistical differences between the intervention group and the comparator group (RR 0.42, 95% CI 0.21 to 0.82, six RCTs; RR 0.38, 95% CI 0.23 to 0.64, five retrospective studies with a control group), that is, CHM plus conventional western therapy appeared better than conventional western therapy alone in reducing aggravation rate. In addition, compared with conventional western therapy, CHM plus conventional western therapy had potential advantages in increasing the recovery rate and shortening the duration of fever, cough and fatigue, improving the negative conversion rate of nucleic acid test, and increasing the improvement rate of chest CT manifestations and shortening the time from receiving the treatment to the beginning of chest CT manifestations improvement. For adverse events, pooled data showed that there were no statistical differences between the CHM and the control groups. Conclusion: Current low certainty evidence suggests that there maybe a tendency that CHM plus conventional western therapy is superior to conventional western therapy alone. The use of CHM did not increase the risk of adverse events.
引用
- Liang SB, Zhang YY, Shen C, et al. Chinese Herbal Medicine Used With or Without Conventional Western Therapy for COVID-19: An Evidence Review of Clinical Studies. Front Pharmacol. 2021. PMID: 33716720. doi:10.3389/fphar.2020.583450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。